Products for Research Use Only
RegisterLogin

Almonertinib

CAT: 0804-HY-112823-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112823-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM) . Almonertinib is used for the research of the non-small cell lung cancer[1][2].
CAS Number
1899921-05-1
Product Name Alternative
HS-10296
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hs-10296.html
Purity
99.83
Solubility
DMSO : 80 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2
Molecular Formula
C30H35N7O2
Molecular Weight
525.64
References & Citations
[1]Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne) . 2017 Jan 18;3:76.|[2]Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17 (1) :38.|[3]Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020; S1556-0864 (20) 30714-0.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Citation 01
Biol Methods Protoc. 2025 Feb 13;10 (1) :bpaf012.|Breast Cancer Res Treat. 2025 Jun;211 (2) :467-478.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Front Pharmacol. 2021 May 14;12:671328.|SSRN. 2025 Sep 25.|Transl Lung Cancer Res. 2025 Jun 30;14 (6) :2159-2179.|Patent. US20220177473A1.

Alternative Products

CatalogName
BUP12672-01Almonertinib
GTR19166725-01Almonertinib mesylate
JKD09603-01Almonertinib hydrochloride
A22232-500Almonertinib 500mg
A22232-100Almonertinib 100mg
A22232-50Almonertinib 50mg
AR-A05958-01Almonertinib-d6
A22232-5Almonertinib 5mg
A22232-25Almonertinib 25mg
A22232-10Almonertinib 10mg

Popular Products